JOUNCE THERAPEUTICS INC (JNCE)
US4811161011 - Common Stock
ChartMill assigns a Buy % Consensus number of 80% to JNCE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.65. This target is -12.29% below the current price.
JNCE was analyzed by 13 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about JNCE.
In the previous month the buy percentage consensus was at a similar level.
JNCE was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-02-24 | SMBC Nikko | Downgrade | Outperform -> Neutral |
| 2023-02-23 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-01-03 | Piper Sandler | Maintains | Overweight |
| 2022-11-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2022-08-31 | Raymond James | Maintains | Strong Buy |
| 2022-08-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | Baird | Downgrade | Outperform -> Neutral |
| 2022-05-06 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-02-04 | Cowen & Co. | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | Raymond James | Maintains | Outperform |
| 2021-09-14 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2021-03-15 | Piper Sandler | Initiate | Overweight |